This article is more than 5 years old. Information may no longer be current.
Wright Medical receives FDA approval for Augment bone graft
Click Here to Manage Email Alerts
Wright Medical Group Inc. announced FDA premarket approval for its Augment bone graft, which can be used as an alternative to autograft for ankle or hindfoot fusion indications.
According to a company press release, Augment bone graft is the first clinically proven protein therapeutic to come to the U.S. orthopedics market in more than a decade and has an estimated market opportunity of approximately $300 million in the United States. The bone graft uses a combination of recombinant human platelet-derived growth factor (rhPDGF) and beta-tricalcium phosphate and can help patients avoid secondary surgical sites for the harvest of autograft tissue.
“The FDA approval of Augment marks a capstone achievement that demonstrates the strength of our science and provides a breakthrough therapeutic options as an alternative to autograft in ankle and hindfoot fusion procedures,” Robert Palmisano, president and CEO of Wright Medical, stated in the release. “We will begin commercial sale and distribution of Augment in the United States and believe this product, as well as the PDGF technology platform, will be important drivers of the long-term growth of our business for years to come.”
Reference: www.wmt.com